Suppr超能文献

地西他滨和吉西他滨二戊酸酯前药的渗透性、稳定性及抗HIV-1活性的表征

Characterization of permeability, stability and anti-HIV-1 activity of decitabine and gemcitabine divalerate prodrugs.

作者信息

Clouser Christine L, Bonnac Laurent, Mansky Louis M, Patterson Steven E

机构信息

Institute for Molecular Virology, University of Minnesota, Minneapolis, MN, USA.

出版信息

Antivir Chem Chemother. 2014 Dec 16;23(6):223-30. doi: 10.3851/IMP2682.

Abstract

BACKGROUND

Over 25 drugs have been approved for the treatment of HIV-1 replication. All but one of these drugs is delivered as an oral medication. Previous studies have demonstrated that two drugs, decitabine and gemcitabine, have potent anti-HIV-1 activities and can work together in synergy to reduce HIV-1 infectivity via lethal mutagenesis. For their current indications, decitabine and gemcitabine are delivered intravenously.

METHODS

As an initial step towards the clinical translation of these drugs for the treatment of HIV-1 infection, we synthesized decitabine and gemcitabine prodrugs in order to increase drug permeability, which has generally been shown to correlate with increased bioavailability in vivo. In the present study we investigated the permeability, stability and anti-HIV-1 activity of decitabine and gemcitabine prodrugs and selected the divalerate esters of each as candidates for further investigation.

RESULTS

Our results provide the first demonstration of divalerate prodrugs of decitabine and gemcitabine that are readily permeable, stable and possess anti-HIV-1 activity.

CONCLUSIONS

These observations predict improved oral availability of decitabine and gemcitabine, and warrant further study of their ability to reduce HIV-1 infectivity in vivo.

摘要

背景

已有超过25种药物被批准用于治疗HIV-1复制。除一种药物外,其他所有药物均通过口服给药。先前的研究表明,地西他滨和吉西他滨这两种药物具有强大的抗HIV-1活性,并且可以协同作用,通过致死性诱变降低HIV-1的感染性。就其目前的适应症而言,地西他滨和吉西他滨通过静脉给药。

方法

作为将这些药物用于治疗HIV-1感染进行临床转化的第一步,我们合成了地西他滨和吉西他滨的前药,以提高药物通透性,一般来说,药物通透性与体内生物利用度的提高相关。在本研究中,我们研究了地西他滨和吉西他滨前药的通透性、稳定性及抗HIV-1活性,并选择了每种药物的二戊酸酯作为进一步研究的候选药物。

结果

我们的结果首次证明了地西他滨和吉西他滨的二戊酸酯前药具有良好的通透性、稳定性并具备抗HIV-1活性。

结论

这些观察结果预示着地西他滨和吉西他滨的口服可用性将会提高,并且有必要进一步研究它们在体内降低HIV-1感染性的能力。

相似文献

7
Are 5'-O-carbamate-2',3'-dideoxythiacytidine new anti-HIV and anti-HBV nucleoside drugs or prodrugs?
Bioorg Med Chem Lett. 2003 Aug 4;13(15):2459-63. doi: 10.1016/s0960-894x(03)00496-7.

引用本文的文献

2
Distinct Antiretroviral Mechanisms Elicited by a Viral Mutagen.病毒诱变引发的独特抗逆转录病毒机制。
J Mol Biol. 2021 Sep 3;433(18):167111. doi: 10.1016/j.jmb.2021.167111. Epub 2021 Jun 18.
8
Lack of mutational hot spots during decitabine-mediated HIV-1 mutagenesis.地西他滨介导的HIV-1诱变过程中缺乏突变热点。
Antimicrob Agents Chemother. 2015 Nov;59(11):6834-43. doi: 10.1128/AAC.01644-15. Epub 2015 Aug 17.

本文引用的文献

1
Back to the future: revisiting HIV-1 lethal mutagenesis.回到未来:重新审视 HIV-1 致死性诱变。
Trends Microbiol. 2013 Feb;21(2):56-62. doi: 10.1016/j.tim.2012.10.006. Epub 2012 Nov 27.
9
Discovery of drugs that possess activity against feline leukemia virus.发现具有抗猫白血病病毒活性的药物。
J Gen Virol. 2012 Apr;93(Pt 4):900-905. doi: 10.1099/vir.0.039909-0. Epub 2012 Jan 18.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验